Automated stem cell-derived organoid platforms for disease modeling

Complex diseases arise from genetic, environmental, and lifestyle factors, the combination of which is difficult to model. Conventional animal and 2D cell culture models have limitations in scalability, reproducibility, or human relevance. Human-induced pluripotent stem cells (iPSCs) can be differentiated into 3D organoids that better mimic human biology. However, organoid protocols can be lengthy, variable, and labor-intensive, limiting high-throughput applications. Suspension bioreactors and multilineage differentiation have improved yield and function, but challenges remain in tissue maturity, vascularization, and consistency. Automated high-throughput liquid handling systems are emerging as a solution, enabling large-scale, reproducible production. Here, we discuss how combining iPSC-derived organoids with automation is poised to transform disease modeling and drug development.